Nam Su Youn, Jeon Seong Woo, Jung Deuk Kju, Heo Sung-Jae
Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.
Department of Otorhinolaryngology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.
Infect Chemother. 2022 Sep;54(3):504-516. doi: 10.3947/ic.2022.0089.
This study aimed to determine factors affecting serum levels of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies 2 months after coronavirus disease 2019 (COVID-19) vaccination in young and middle aged healthy adults.
Healthcare workers who have no history of SARS-CoV-2 infection, were enrolled at 2 months after second shot of BNT162b2 mRNA COVID-19 vaccine. Antibody immunoglobulin G against the spike protein subunit of SARS-CoV-2 was semi-quantitatively measured using 4 commercial enzyme-linked immunosorbent assay kits. Factors affecting anti-SARS-CoV-2 antibodies levels were investigated.
Fifty-one persons (22 - 54 years, male sex; 19.6%) were enrolled and all participants acquired anti-SARS-CoV-2 antibodies in four diagnostic kits. Anti-SARS-CoV-2 antibodies were strongly correlated between diagnostic kits; SG Medical and Genscript (r = 0.942), SG Medical and HB Healthcare (r = 0.903), and HB Healthcare and Genscript (r = 0.868). We investigated factors affecting antibody level using SG medical kit. The median inhibition was 93.1%, and 84.0% of participants showed >90.0% inhibition. Systemic adverse event severity had no association with the anti-SARS-CoV-2 antibodies level. Antibody level was inversely correlated with weight (-0.312, = 0.027), body mass index (BMI) (r = -0.303, = 0.032), and body surface area (r = -0.285, = 0.044). In multivariate analysis, the upper 50% of anti-SARS-CoV-2 antibodies (≥93.1%) was inversely associated with weight (odds ratio [OR]: 0.19; 95% confidence interval [CI]: 0.04 - 0.83 in weight ≥55kg) and BMI (OR: 0.12; 95% CI: 0.03 - 0.61 in BMI ≥22 kg/m²).
Anti-SARS-CoV-2 antibody was inversely correlated with weight and BMI, which may be used as a marker to predict immune response of BNT162b2 mRNA vaccination in young and middle aged adults.
ClinicalTrials.gov Identifier: NCT05083026.
本研究旨在确定影响年轻及中年健康成年人接种2019冠状病毒病（COVID-19）疫苗2个月后抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体血清水平的因素。
选取无SARS-CoV-2感染史的医护人员，在接种第二剂BNT162b2 mRNA COVID-19疫苗2个月后纳入研究。使用4种商用酶联免疫吸附测定试剂盒半定量检测针对SARS-CoV-2刺突蛋白亚基的抗体免疫球蛋白G。研究影响抗SARS-CoV-2抗体水平的因素。
共纳入51人（22 - 54岁，男性；19.6%），所有参与者在4种诊断试剂盒中均检测到抗SARS-CoV-2抗体。各诊断试剂盒之间的抗SARS-CoV-2抗体呈强相关性；SG Medical与金斯瑞（r = 0.942）、SG Medical与HB Healthcare（r = 0.903）、HB Healthcare与金斯瑞（r = 0.868）。我们使用SG医疗试剂盒研究影响抗体水平的因素。抑制率中位数为93.1%，84.0%的参与者抑制率>90.0%。全身不良事件严重程度与抗SARS-CoV-2抗体水平无关。抗体水平与体重（-0.312，P = 0.027）、体重指数（BMI）（r = -0.303，P = 0.032）和体表面积（r = -0.285，P = 0.044）呈负相关。多因素分析中，抗SARS-CoV-2抗体水平较高的50%（≥93.1%）与体重（优势比[OR]：0.19；95%置信区间[CI]：体重≥55kg时为0.04 - 0.83）和BMI（OR：0.12；95%CI：BMI≥22kg/m²时为0.03 - 0.61）呈负相关。
抗SARS-CoV-2抗体与体重和BMI呈负相关，这可作为预测年轻及中年成年人BNT162b2 mRNA疫苗免疫反应的标志物。
ClinicalTrials.gov标识符：NCT05083026。
